Introduction to SLC16A11 (G162515)

Target Name: SLC16A11

NCBI ID: G162515

SLC16A11

Introduction to SLC16A11

SLC16A11 is a gene that encodes a member of the monocarboxylate transporter family, specifically known as SLC16A11 protein. This protein is primarily expressed in the liver and pancreatic islets, and it is involved in the transport of small molecules, particularly monocarboxylates such as pyruvate and lactate. Recent research has identified SLC16A11 as a potential drug target or biomarker for several diseases. In this article, we will delve deeper into the role of SLC16A11 and explore its significance in various medical conditions.

The Function of SLC16A11:
SLC16A11 plays a crucial role in maintaining metabolic homeostasis by regulating the transportation of monocarboxylates across cell membranes. Monocarboxylates are vital energy substrates for various tissues, including muscles and the brain. By facilitating the movement of monocarboxylates in and out of cells, SLC16A11 maintains the necessary supply of energy-rich molecules, ensuring cellular functions are adequately supported.

SLC16A11 as a Drug Target:
Research has discovered that SLC16A11 may serve as a potential drug target for several metabolic disorders, including type 2 diabetes and obesity. The genetic variation in SLC16A11 has been linked to an increased risk of developing these conditions. Studies have shown that SLC16A11 variants lead to impaired lactate transport, which subsequently affects glucose metabolism.

In light of these findings, developing drugs that modulate SLC16A11 activity could provide a therapeutic strategy for managing type 2 diabetes and obesity. By targeting SLC16A11, it may be possible to restore proper glucose metabolism and prevent the onset or progression of these metabolic disorders.

Biomarker Potential of SLC16A11:
In addition to its role as a drug target, SLC16A11 also shows promising potential as a biomarker for certain diseases. Biomarkers are measurable indicators that can provide valuable information about the presence, severity, or progression of a disease. Identifying reliable biomarkers is crucial for early diagnosis, monitoring treatment response, and designing personalized therapies.

SLC16A11 could serve as a biomarker for hepatocellular carcinoma (HCC), the most common type of liver cancer. Various studies have observed altered expression levels of SLC16A11 in HCC patients compared to healthy individuals. Elevated SLC16A11 expression has been correlated with tumor progression and poor prognosis in HCC patients. Monitoring SLC16A11 levels may aid in the early detection of HCC and provide insights into its aggressiveness.

The Role of SLC16A11 in Neurological Disorders:
Recent research has also shed light on the involvement of SLC16A11 in neurological disorders, particularly Alzheimer's disease (AD). AD is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta plaques and tau tangles in the brain. Studies have shown that SLC16A11 is involved in the regulation of amyloid-beta metabolism and clearance.

Reduced SLC16A11 expression has been observed in AD patients, suggesting a potential role in the pathogenesis of the disease. Alterations in SLC16A11 levels may affect the transport of lactate and other metabolites crucial for energy metabolism in the brain. Consequently, targeting SLC16A11 could offer a novel therapeutic approach for managing AD and other neurodegenerative disorders.

Conclusion:
SLC16A11, a gene encoding the SLC16A11 protein, plays a significant role in regulating the transport of monocarboxylates and maintaining metabolic homeostasis. Its implications as a drug target or biomarker have garnered attention in various medical conditions, including type 2 diabetes, obesity, hepatocellular carcinoma, and neurodegenerative disorders like Alzheimer's disease.

The identification of SLC16A11 as a potential therapeutic target or biomarker opens up new avenues for drug development, early diagnosis, and personalized treatment strategies. Further research is needed to elucidate the mechanisms underlying SLC16A11's involvement in these diseases, and to explore the full potential of targeting this gene for improved patient outcomes.

Protein Name: Solute Carrier Family 16 Member 11

Functions: Proton-linked monocarboxylate transporter. It catalyzes the transport of pyruvate across the plasma membrane (PubMed:28666119). Probably involved in hepatic lipid metabolism: overexpression results in an increase of triacylglycerol(TAG) levels, small increases in intracellular diacylglycerols and decreases in lysophosphatidylcholine, cholesterol ester and sphingomyelin lipids (PubMed:24390345)

The "SLC16A11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC16A11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets